A previous study of TCGA patients with a variety of tumor types identified an association between high C19orf57 expression with superior survival on cisplatin therapy compared to low C19orf57 expression in cervical squamous cell carcinoma and endocervical adenocarcinoma [16]. The gene discussed is BRME1; the disease is neoplasm.